csirt@kutim:~/threat-intel/cve/CVE-2025-11578

Katalog CVE

CVSS 7.2 · High EPSS 0,71%

Kerentanan Improper Link Resolution Before File Access ('Link Following') pada github enterprise server. Skor CVSS 3.1 7.2 (High) menurut NVD.

Deskripsi (NVD)

A privilege escalation vulnerability was identified in GitHub Enterprise Server that allowed an authenticated Enterprise admin to gain root SSH access to the appliance by exploiting a symlink escape in pre-receive hook environments. By crafting a malicious repository and environment, an attacker could replace system binaries during hook cleanup and execute a payload that adds their own SSH key to the root user’s authorized keys—thereby granting themselves root SSH access to the server. To exploit this vulnerability, the attacker needed to have enterprise admin privileges. This vulnerability affected all versions of GitHub Enterprise Server prior to 3.19, and was fixed in versions 3.14.20, 3.15.15, 3.16.11, 3.17.8, 3.18.2. This vulnerability was reported via the GitHub Bug Bounty program.

Rincian

Terbit di NVD
10 November 2025
Terakhir diubah
7 Oktober 2026
Status NVD
Analyzed
CVSS 3.1
7.2 (High), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-59: Improper Link Resolution Before File Access ('Link Following')
EPSS (30 hari)
0,71% peluang dieksploitasi; lebih tinggi dari 52,1% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
github enterprise server Versi 3.14.0 hingga sebelum 3.14.20
github enterprise server Versi 3.15.0 hingga sebelum 3.15.15
github enterprise server Versi 3.16.0 hingga sebelum 3.16.11
github enterprise server Versi 3.17.0 hingga sebelum 3.17.8
github enterprise server Versi 3.18.0 hingga sebelum 3.18.2

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 8 Okt 2026, 12:26 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.